Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track QUCY with free AI briefings, catalyst countdowns, and dilution alerts.

QUCY · Quantum Cyber N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5M Cash on Hand
2.6mo Cash Runway
Follow QUCY by email Get an email when QUCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about QUCY, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
dermo cosmetic product Hypotrichosis Phase 4 · NCT07776028 Completed
Firibastat Hypertension Phase 3 · NCT04277884 Completed
Firibastat (QGC001) Period 1 Hypertension (HTN) Phase 3 · NCT04857840 Terminated
Dendritic Cell Vaccination Breast Cancer Phase 1/2 · NCT00879489 Unknown
Ultra-micronized Palmitoyl Ethylamine (PEA)… Mast Cell Activation Syndrome Phase 2 · NCT05652907 Terminated
QGC001 Hypertension Phase 2 · NCT03198793 Completed
Lucid-21-302 Healthy Participants Phase 1 · NCT05821387 Completed
QGC001 [(3S,3'S)-4,4'-dithiobis… Essential Hypertension Phase 1 · NCT01900184 Completed

Also used in these trials (approved or third-party drugs, not QUCY's own candidates): Ramipril.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

QUCY holds $5M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.7M/quarter from operations, an estimated runway of 2.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QUCY files for a raise →

👥 Who Owns QUCY

Insiders 65.6% Institutions 3.1% Public and other holders 31.3%
HolderTypeShares% of sharesAs of
David E. Lazar
Chief Executive Officer, Director, 10% o · +1.88M options
Insider 55,057,500 63.11% 2026-08-05
Alexander Gurevich Institution (13G, 5%+) 2,718,543 3.12% 2026-06-03
Kevin Michael Donahue
10% owner
Insider 685,000 0.79% 2025-10-17
Guido Baechler
Chief Executive Officer, Director
Insider 605,058 0.69% 2026-02-13
William J Caragol
Chief Financial Officer · +425,000 options
Insider 367,899 0.42% 2026-02-13
Avraham Ben-Tzvi
Director
Insider 251,400 0.29% 2026-07-31
David Natan
Director · +190,840 options
Insider 137,141 0.16% 2026-05-08
Heinrich Dreismann
Director
Insider 64,700 0.07% 2026-02-13
Gregory J Tibbitts
Director
Insider 55,875 0.06% 2026-02-13
Hans Hekland
Director
Insider 45,000 0.05% 2026-01-01

Share count 87,241,735 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full QUCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QUCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.